Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Oct;116(3):1957–1964. doi: 10.1111/j.1476-5381.1995.tb16398.x

Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo.

R A Mathôt 1, E M Van der Wenden 1, W Soudijn 1, A P IJzerman 1, M Danhof 1
PMCID: PMC1908942  PMID: 8640332

Abstract

1. The purpose of the present study was to quantify the cardiovascular effects of the 2'-, 3'-, 5'-deoxyribose analogues of the selective adenosine A1 receptor agonist, N6-cyclopentyladenosine (CPA) in vivo. The blood concentration-effect relationships of the compounds were assessed in individual rats and correlated to their receptor binding characteristics. 2. The pharmacokinetics and pharmacodynamics of the compounds were determined after a single intravenous infusion of 0.80 mg kg (-1) (63 micromol kg(-1)of 2' dCPA. The heart rate (HR) and mean arterial blood pressure (MAP) were monitored continuously during the experiment and serial arterial blood samples were taken for analysis of drug concentration. 3. The relationship between blood concentrations and the reductions in both heart rate and blood pressure were described according to the sigmoidal Emax model. For the bradycardiac effect, the potencies based on free drug concentrations (EC50,u) of 5'dCPA, 3'dCPA, 2'dCPAin blood were 5.9 +/- 1.7, 18 +/- 4 and 260 +/- 70 ng ml (-1) (19 +/- 6, 56 +/- 11 and 830 +/- 210 nM), respectively, and correlated well with the adenosine A1 receptor affinity in vitro. The Emax value of 2'dCPA was significantly less than those of the other compounds, suggesting that this compound may be regarded as a partial agonist when compared to the other analogues. The rank order of the maximal reduction in heart rate of the compounds corresponded well with the order of the GTP-shifts, as determined in vitro. 4. It is concluded that deoxyribose derivatives of CPA may be partial agonists for the adenosine A1 receptor and may serve as tools for further investigation of adenosine receptor partial agonism in vivo.

Full text

PDF
1957

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abiru T., Yamaguchi T., Watanabe Y., Kogi K., Aihara K., Matsuda A. The antihypertensive effect of 2-alkynyladenosines and their selective affinity for adenosine A2 receptors. Eur J Pharmacol. 1991 Apr 10;196(1):69–76. doi: 10.1016/0014-2999(91)90410-r. [DOI] [PubMed] [Google Scholar]
  2. Belardinelli L., Fenton R. A., West A., Linden J., Althaus J. S., Berne R. M. Extracellular action of adenosine and the antagonism by aminophylline on the atrioventricular conduction of isolated perfused guinea pig and rat hearts. Circ Res. 1982 Nov;51(5):569–579. doi: 10.1161/01.res.51.5.569. [DOI] [PubMed] [Google Scholar]
  3. Coffin V. L., Spealman R. D. Behavioral and cardiovascular effects of analogs of adenosine in cynomolgus monkeys. J Pharmacol Exp Ther. 1987 Apr;241(1):76–83. [PubMed] [Google Scholar]
  4. Dingemanse J., Danhof M., Breimer D. D. Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther. 1988;38(1):1–52. doi: 10.1016/0163-7258(88)90101-5. [DOI] [PubMed] [Google Scholar]
  5. Evans D. B., Schenden J. A., Bristol J. A. Adenosine receptors mediating cardiac depression. Life Sci. 1982 Nov 29;31(22):2425–2432. doi: 10.1016/0024-3205(82)90746-9. [DOI] [PubMed] [Google Scholar]
  6. Fozard J. R., Carruthers A. M. Adenosine A3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat. Br J Pharmacol. 1993 May;109(1):3–5. doi: 10.1111/j.1476-5381.1993.tb13522.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hamilton H. W., Taylor M. D., Steffen R. P., Haleen S. J., Bruns R. F. Correlation of adenosine receptor affinities and cardiovascular activity. Life Sci. 1987 Nov 16;41(20):2295–2302. doi: 10.1016/0024-3205(87)90542-x. [DOI] [PubMed] [Google Scholar]
  8. Holford N. H., Sheiner L. B. Kinetics of pharmacologic response. Pharmacol Ther. 1982;16(2):143–166. doi: 10.1016/0163-7258(82)90051-1. [DOI] [PubMed] [Google Scholar]
  9. IJzerman A. P., van der Wenden E. M., von Frijtag Drabbe Künzel J. K., Mathôt R. A., Danhof M., Borea P. A., Varani K. Partial agonism of theophylline-7-riboside on adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Dec;350(6):638–645. doi: 10.1007/BF00169369. [DOI] [PubMed] [Google Scholar]
  10. Jacobson K. A., Trivedi B. K., Churchill P. C., Williams M. Novel therapeutics acting via purine receptors. Biochem Pharmacol. 1991 May 15;41(10):1399–1410. doi: 10.1016/0006-2952(91)90555-j. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kent R. S., De Lean A., Lefkowitz R. J. A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol. 1980 Jan;17(1):14–23. [PubMed] [Google Scholar]
  12. Kusachi S., Thompson R. D., Olsson R. A. Ligand selectivity of dog coronary adenosine receptor resembles that of adenylate cyclase stimulatory (Ra) receptors. J Pharmacol Exp Ther. 1983 Nov;227(2):316–321. [PubMed] [Google Scholar]
  13. Lahti R. A., Figur L. M., Piercey M. F., Ruppel P. L., Evans D. L. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol. 1992 Sep;42(3):432–438. [PubMed] [Google Scholar]
  14. Martens D., Lohse M. J., Rauch B., Schwabe U. Pharmacological characterization of A1 adenosine receptors in isolated rat ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1987 Sep;336(3):342–348. doi: 10.1007/BF00172688. [DOI] [PubMed] [Google Scholar]
  15. Mathôt R. A., Appel S., van Schaick E. A., Soudijn W., IJzerman A. P., Danhof M. High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. J Chromatogr. 1993 Oct 22;620(1):113–120. doi: 10.1016/0378-4347(93)80058-c. [DOI] [PubMed] [Google Scholar]
  16. Mathôt R. A., Van den Aarsen B. C., Soudijn W., Breimer D. D., Ijzerman A. P., Danhof M. Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats. J Pharmacol Exp Ther. 1995 Apr;273(1):405–414. [PubMed] [Google Scholar]
  17. Mathôt R. A., van Schaick E. A., Langemeijer M. W., Soudijn W., Breimer D. D., Ijzerman A. P., Danhof M. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther. 1994 Feb;268(2):616–624. [PubMed] [Google Scholar]
  18. Oei H. H., Ghai G. R., Zoganas H. C., Stone G. A., Zimmerman M. B., Field F. P., Williams M. Correlation between binding affinities for brain A1 and A2 receptors of adenosine agonists and antagonists and their effects on heart rate and coronary vascular tone. J Pharmacol Exp Ther. 1988 Dec;247(3):882–888. [PubMed] [Google Scholar]
  19. Stiles G. L. A1 adenosine receptor-G protein coupling in bovine brain membranes: effects of guanine nucleotides, salt, and solubilization. J Neurochem. 1988 Nov;51(5):1592–1598. doi: 10.1111/j.1471-4159.1988.tb01129.x. [DOI] [PubMed] [Google Scholar]
  20. Webb R. L., Barclay B. W., Graybill S. C. Cardiovascular effects of adenosine A2 agonists in the conscious spontaneously hypertensive rat: a comparative study of three structurally distinct ligands. J Pharmacol Exp Ther. 1991 Dec;259(3):1203–1212. [PubMed] [Google Scholar]
  21. Webb R. L., McNeal R. B., Jr, Barclay B. W., Yasay G. D. Hemodynamic effects of adenosine agonists in the conscious spontaneously hypertensive rat. J Pharmacol Exp Ther. 1990 Sep;254(3):1090–1099. [PubMed] [Google Scholar]
  22. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]
  23. van Galen P. J., van Bergen A. H., Gallo-Rodriguez C., Melman N., Olah M. E., IJzerman A. P., Stiles G. L., Jacobson K. A. A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol. 1994 Jun;45(6):1101–1111. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES